Adverse Event Management

Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.

Veno-occlusive disease or sinusoidal obstruction syndrome is commonly associated as a complication with transplant in pediatric patients but can also be seen with chemotherapy alone.

Elizabeth R. Cullen, MSN, ARNP, talks severe oral mucositis management for patients with locally advanced head and neck cancer.

Meredith Cummings, BSN, RN, OCN, discusses the potential benefit of machine learning in predicting symptoms for patients with head and neck cancer.

Kara Morris, MSN, RN, OCN; and Christine Wylie, MSN, RN, OCN, discuss their research on oral cryotherapy as a mucositis mitigation strategy.

Appropriate monitoring of infusion-related reactions requires up-to-date knowledge of the latest criteria for adverse event management, health system policies, and protocols for reporting.

Donna Catamero, ANP-BC, OCN, CCRC, highlights best nursing practices with teclistamab.

Research published in JAMA Oncology suggest that acute radiation dermatitis may be the result of a common skin bacterium and prevented with a low-cost topical treatment.

Most patients experienced at least a 50% reduction in incontinence episodes at 6 months with the miniature device.

Phase 2a trial data suggest that single-dose URO-902 may be an effective, and safe, treatment for women experiencing difficulties with bladder control.

Radioligand therapy with 177Lu-PSMA-I&T elicited favorable PSA responses and a safety profile similar to PSMA-617.

Kathleen Gander DNP, APRN, CNS; and Sarah Middlekauff, MSN, RN, OCN, relay their experiences in implementing a hepatic artery infusion pump educational intervention for oncology nurses.

Data presented during the ONS Annual Congress offers guidance for nurses caring for patients receiving darolutamide, docetaxel, and androgen deprivation therapy.

Rita Deimler, MSN, ANP-BC, outlines best cardiac event monitoring and management practices for patients receiving the CDK4/6 inhibitor ribociclib.

Managing ocular-related adverse effects with mirvetuximab soravtansine is key to helping patients with ovarian cancer stay on treatment.

An analysis of the cilta-cel safety profile yielded promising results, according to nurse investigators.

Victoria R. Crowder, BSN, RN, and co-investigators, highlight existing gaps in the understanding of malnutrition risks facing patients with acute myeloid leukemia and myelodysplastic syndromes.

Monitoring patients for cytokine release syndrome is a key aspect of caring for patients receiving teclistamab.

Specialists highlight the best practices and latest treatment regimens for patients presenting with myelofibrosis, polycythemia vera, and essential thrombocythemia.

Milademetan, a MDM2 inhibitor, is associated with thrombocytopenia. An intermittent dosing schedule may help mitigate that adverse event.

Sarah Yenser Wood, RN, MSN, ANP, AOCNP, leads a nursing panel on adverse event management in renal cell carcinoma.

Omidubicel has been approved to quicken the recovery of neutrophils and reduce the risk of infection following stem cell transplant.

Early coordination with multiple specialty teams can maximize outcomes and improve quality of life for patients with complex metastatic disease.

Patients with unresectable pancreatic cancers and cholangiocarcinoma face poor prognoses, but systemic treatment continues to evolve.

Olanzapine demonstrated efficacy in improving appetite and weight gain in patients receiving cytotoxic chemotherapies.

Hematologists have developed a framework of the core symptoms caregivers should look out for when caring for a patient who has just received CAR T-cell therapy.

The implementation of a nonpharmacologic pain intervention bundle helped decrease opioid use among patients recovering from gynecologic and urologic surgeries at a comprehensive cancer center.

The International Pediatric Fever and Neutropenia Guideline Panel have reconvened and released a 2023 clinical practice guideline update.

Siltuximab led to the complete resolution of cytokine release syndrome in 5 out of 6 patients, with a median time to complete response within 1 hour.

Linh Nguyen BSN, RN, OCN, BMTCN, highlights the benefits of prospective toxicity data collection for patients undergoing bone marrow transplantation.